Auron to Present AUTX-703 Preclinical Data at 2024 ENA Symposium

Auron Therapeutics, a biotechnology firm headquartered in NEWTON, Mass., has unveiled plans to present significant updates on its lead program at the upcoming 36th EORTC-NCI-AACR (ENA) Symposium, scheduled for October 23-25, 2024 in Barcelona, Spain. The presentation will feature preclinical data concerning AUTX-703, a promising oral medication designed to selectively degrade KAT2A/B, a histone acetyltransferase linked to various cancer types, including small cell lung cancer (SCLC).

Auron's upcoming presentation will include both in vitro (test tube) and in vivo (living organism) data on AUTX-703, highlighting its potential effectiveness in targeting KAT2A/B. This enzyme plays a crucial role in the proliferation of several tumors. The company's research has shown that AUTX-703 can induce significant changes in cell states and inhibit tumor growth in SCLC models.

The formal presentation details are as follows:
- Abstract Title: "AUTX-703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Profound Cell State Changes and Inhibits Growth on Small Cell Lung Cancer (SCLC) Model Systems"
- Poster Session: Molecular Targeted Agents
- Session Date and Time: Wednesday, October 23, from 12:00 - 7:00 p.m. CET

Auron Therapeutics positions itself as a patient-focused company, heavily reliant on its platform technology, named AURIGIN™. This proprietary platform leverages artificial intelligence (AI) and machine learning to identify and compare the states of normal and cancerous cells. This comparison allows the identification of novel cancer targets, the development of optimal models, and the discovery of biomarkers, which are essential for the accurate selection of patients for clinical trials.

The company's pipeline is built on this innovative platform, with AUTX-703 leading the way. AUTX-703 aims to treat not only solid tumors such as small cell lung cancer and neuroendocrine prostate cancer but also hematologic malignancies, including acute myeloid leukemia.

Auron’s approach showcases its commitment to revolutionizing cancer treatment by targeting the specific oncogenic states of cancer cells, making therapies more effective and tailored to individual patient needs. The company is on track to submit an Investigational New Drug (IND) application for AUTX-703 by the end of 2024, with plans to commence clinical trials in early 2025. This progression marks a significant step forward in their mission to advance targeted cancer therapies.

In summary, Auron Therapeutics is set to share compelling preclinical data on AUTX-703 at a key symposium, underscoring its potential as a novel treatment for various cancers. The company’s utilization of AI and machine learning through its AURIGIN™ platform exemplifies its cutting-edge approach to oncology, positioning it at the forefront of developing next-generation cancer therapies.